QUININE SULFATE

Post-LOE

quinine sulfate

PharmaIN

ANDAORALCAPSULE

Approved

Jul 2015

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

QUININE SULFATE (quinine sulfate) by PharmaIN is 12. Approved for uncomplicated plasmodium falciparum malaria. First approved in 2015.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

12.1 Mechanism of Action Quinine is an antimalarial agent [ see ]. 12.2 Pharmacodynamics QTc interval prolongation was studied in a double-blind, multiple dose, placebo-and positive-controlled crossover study in young (N=13, 20 to 39 years) and elderly (N=13, 65 to 78 years) subjects. After 7 days…

Worked on QUININE SULFATE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

QUININE SULFATE

Mechanism of Action

Indications (1)

Clinical Trials (1)